From September 2 to 4, the 16th Global Regulatory Science Conference was held in Beijing. Regulators, research institutes and industry experts from more than 10 countries and regions, including China, the US, and Europe, conducted in-depth exchanges on emerging technologies and smart regulation topics, focusing on cutting-edge fields such as artificial intelligence, new methodologies, organ chips, and nanotechnology. Yang Sheng, deputy director of the State Drug Administration, attended the conference and delivered a speech. Yang Sheng stressed that in the face of the new situation and challenges of scientific and technological innovation and industrial transformation, the field of global regulatory science should strengthen collaboration, deepen cutting-edge research, enhance exchanges and mutual learning, forge consensus among all parties, jointly enhance drug supervision capabilities, promote the high-quality development of the global pharmaceutical industry, and ensure the safety and effectiveness of drug use by the public in all countries.

From September 2 to 4, the 16th Global Regulatory Science Conference was held in Beijing. Regulators, research institutes and industry experts from more than 10 countries and regions, including China, the US, and Europe, conducted in-depth exchanges on emerging technologies and smart regulation topics, focusing on cutting-edge fields such as artificial intelligence, new methodologies, organ chips, and nanotechnology. Yang Sheng, deputy director of the State Drug Administration, attended the conference and delivered a speech. Yang Sheng stressed that in the face of the new situation and challenges of scientific and technological innovation and industrial transformation, the field of global regulatory science should strengthen collaboration, deepen cutting-edge research, enhance exchanges and mutual learning, forge consensus among all parties, jointly enhance drug supervision capabilities, promote the high-quality development of the global pharmaceutical industry, and ensure the safety and effectiveness of drug use by the public in all countries.